How the immune system affects a person's sensitivity to radiotherapy.
Official title: Involvement of the Immune System in Intrinsic Radiosensitivity
Run by Assistance Publique - Hôpitaux de Paris · NCT06826066 · Data updated 2026-11-12
This project tests whether differences in patients' immune cells are linked to who does or does not develop severe side effects after radiotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Créteil, Île-de-France Region) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | May 12, 2027 |
| Study ends | May 12, 2027 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT06826066 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who have been treated with radiotherapy, did not experience grade 2 or higher radiation toxicity, can give informed consent, and are covered by social security are ideal candidates.
✕Probably not a fit
Patients who have already experienced grade 2 or higher radiation toxicity, have active disease progression or relapse, cannot consent, or are under legal protection are unlikely to receive direct benefit from this control-focused project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The effort builds a control cohort (TRANSPROUST) of patients treated with radiotherapy who did not develop severe toxicity and pairs their clinical, dosimetric, and blood-based biological data with an existing registry of radiosensitive patients (PROUST). Participants provide blood samples that will be analyzed for cellular and molecular immune markers. Immune profiles will be compared alongside treatment dose and volume data to try to separate treatment-related from patient-intrinsic causes of toxicity. The aim is to identify immune-related signatures that explain or predict intrinsic radiosensitivity.
Why it matters
Potential benefit: If successful, this could lead to tests that predict who is at higher risk for severe radiation side effects and help personalize radiotherapy to reduce harm.
How similar studies have gone: Some prior research suggests immune responses influence radiation outcomes, but prospective registry-based immune monitoring to pinpoint cellular causes of radiosensitivity remains relatively novel and unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Patients who have been treated with radiotherapy * Absence of toxicity grade 2 or higher * Patients without psychiatric, sociological, family, or geographical difficulties that could interfere with patient compliance to the protocol or follow-up * Information and signed informed consent * Affiliated with social security Exclusion Criteria: * Inability to obtain patient consent * Patient refusing blood sample collection * Patient deprived of liberty or under legal protection (under guardianship, under curatorship) * Patients who have experienced radiation-induced toxicity of grade 2 or higher * Disease progression, relapse * Patient under State Medical Aid
Where it's running
-
Hôpital Henri Mondor, 1 rue Gustave Eiffel,
Créteil, Île-de-France Region, France Recruiting
Study contacts
- Study coordinator: BELKACIMI Mr Yazid, PhD
- Email: yazid.belkacemi@aphp.fr
- Phone: 01 49 81 45 22
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.